Bile Acid Modifications at the Microbe-Host Interface: Potential for Nutraceutical and Pharmaceutical Interventions in Host Health

Annual Review of Food Science and Technology

Volumn 7, Issue , 2016, Pages 313-333

  Joyce, Susan A ^a,b   Gahan, Cormac G M ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Bile acid; Cholesterol; Microbiota; Obesity; Probiotic

Indexed keywords

CHOLESTEROL; DISEASES; ELECTROLYTES; METABOLISM; NUTRITION; PHYSIOLOGY;

BILE ACID; CHOLESTEROL METABOLISM; CLOSTRIDIUM DIFFICILE; HEPATOCELLULAR CARCINOMA; INFLAMMATORY BOWEL DISEASE; MICROBIOTAS; OBESITY; PROBIOTICS;

BODY FLUIDS;

BILE ACID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; PROBIOTIC AGENT;

AGING; DIET; DIETARY SUPPLEMENT; DISEASES; ENERGY METABOLISM; HEALTH STATUS; HUMAN; INTESTINE FLORA; LIVER; METABOLISM; PHARMACEUTICS; PHYSIOLOGY; SIGNAL TRANSDUCTION; WEIGHT GAIN;

AGING; BILE ACIDS AND SALTS; DIET; DIETARY SUPPLEMENTS; DISEASE; ENERGY METABOLISM; GASTROINTESTINAL MICROBIOME; HEALTH STATUS; HUMANS; LIVER; PROBIOTICS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TECHNOLOGY, PHARMACEUTICAL; WEIGHT GAIN;

EID: 84959882996     PISSN: 19411413     EISSN: 19411421     Source Type: Journal    
DOI: 10.1146/annurev-food-041715-033159     Document Type: Article

References (132)

1. Ahmad NN, Pfalzer A, Kaplan LM. 2013. Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. Int. J. Obes. 37:1553-59
2. Albrecht J, Schousboe A. 2005. Taurine interaction with neurotransmitter receptors in the CNS: an update. Neurochem. Res. 30:1615-21
3. Alrefai WA, Gill RK. 2007. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm. Res. 24:1803-23
4. Apro J, Beckman L, Angelin B, Rudling M. 2015. Influence of dietary sugar on cholesterol and bile acid metabolism in the rat: marked reduction of hepatic Abcg5/8 expression following sucrose ingestion. Biochem. Biophys. Res. Commun. 461:592-97
5. Barrett KE, Keely SJ. 2000. Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu. Rev. Physiol. 62:535-72
6. Baxter JD, Webb P. 2006. Metabolism: bile acids heat things up. Nature 439:402-3
7. Begley M, GahanCG, Hill C. 2005. The interaction between bacteria and bile. FEMSMicrobiol. Rev. 29:625-51
8. Begley M, Hill C, GahanCG. 2006. Bile salt hydrolase activity in probiotics. Appl. Environ. Microbiol. 72:1729-38
9. Begley M, Sleator RD, Gahan CG, Hill C. 2005. Contribution of three bile-associated loci, bsh, pva, and btlB, to gastrointestinal persistence and bile tolerance of Listeria monocytogenes. Infect. Immun. 73:894-904
10. Bennett BJ, de Aguiar Vallim TQ, Wang Z, Shih DM, Meng Y, et al. 2013. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 17:49-60
11. Bjarnadottir TK, Gloriam DE, Hellstrand SH, Kristiansson H, Fredriksson R, Schioth HB. 2006. Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. Genomics 88:263-73
12. Bonfleur ML, Borck PC, Ribeiro RA, Caetano LC, Soares GM, et al. 2015. Improvement in the expression of hepatic genes involved in fatty acid metabolism in obese rats supplemented with taurine. Life Sci. 135:15-21
13. Buchwald H, Avidor Y, Braunwald E, Jensen MD, PoriesW, et al. 2004. Bariatric surgery: a systematic review and meta-analysis. JAMA 292:1724-37
14. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, et al. 2015. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517:205-8
15. Calmus Y, Poupon R. 2014. Shaping macrophages function and innate immunity by bile acids: mechanisms and implication in cholestatic liver diseases. Clin. Res. Hepatol. Gastroenterol. 38:550-56
16. Camilleri M. 2015. Bile acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver 9:332-39
17. Cheng S, LarsonMG, McCabe EL, Murabito JM, Rhee EP, et al. 2015. Distinct metabolomic signatures are associated with longevity in humans. Nat. Commun. 6:6791
18. Chiang JY. 2009. Bile acids: regulation of synthesis. J. Lipid Res. 50:1955-66
19. Claesson MJ, Jeffery IB, Conde S, Power SE, O'Connor EM, et al. 2012. Gut microbiota composition correlates with diet and health in the elderly. Nature 488:178-84
20. Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, et al. 2013. Dietary intervention impact on gutmicrobial gene richness. Nature 500:585-88
21. D'Aldebert E, Biyeyeme Bi Mve MJ, Mergey M, Wendum D, Firrincieli D, et al. 2009. Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology 136:1435-43
22. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, et al. 2014. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505:559-63
23. de Aguiar Vallim TQ, Tarling EJ, Edwards PA. 2013. Pleiotropic roles of bile acids inmetabolism. CellMetab. 17:657-69
24. DegirolamoC, Rainaldi S, Bovenga F, Murzilli S, Moschetta A. 2014. Microbiotamodification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep. 7:12-18
25. De Preter V, Arijs I, Windey K, Vanhove W, Vermeire S, et al. 2012. Decreasedmucosal sulfide detoxification is related to an impaired butyrate oxidation in ulcerative colitis. Inflamm. Bowel Dis. 18:2371-80
26. Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, et al. 2012. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10/ mice. Nature 487:104-8
27. Duboc H, Rainteau D, Rajca S, Humbert L, Farabos D, et al. 2012. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol. Motil. 24:513-20, e246-47
28. Duboc H, Rajca S, Rainteau D, Benarous D, Maubert M-A, et al. 2013. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 62:531-39
29. Duro D, Mitchell PD, Kalish LA, Martin C, McCarthy M, et al. 2011. Risk factors for parenteral nutrition-associated liver disease following surgical therapy for necrotizing enterocolitis: A Glaser Pediatric Research Network Study [corrected]. J. Pediatr. Gastroenterol. Nutr. 52:595-600
30. Evans RM, Emsley CL, Gao S, Sahota A, Hall KS, et al. 2000. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 54:240-42
31. Falany CN, Johnson MR, Barnes S, Diasio RB. 1994. Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA:amino acid N-acyltransferase. J. Biol. Chem. 269:19375-79
32. Fang S, Suh JM, Reilly SM, Yu E, Osborn O, et al. 2015. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat. Med. 21:159-65
33. Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, RenooijW, et al. 2011. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60:463-72
34. Goldberg AA, Richard VR, Kyryakov P, Bourque SD, Beach A, et al. 2010. Chemical genetic screen identifies lithocholic acid as an anti-aging compound that extends yeast chronological life span in a TORindependent manner, by modulating housekeeping longevity assurance processes. Aging 2:393-414
35. Guban J, Korver DR, Allison GE, Tannock GW. 2006. Relationship of dietary antimicrobial drug administration with broiler performance, decreased population levels of Lactobacillus salivarius, and reduced bile salt deconjugation in the ileum of broiler chickens. Poult. Sci. 85:2186-94
36. Halmy L, Feher T, Steczek K, Farkas A. 1986. High serum bile acid level in obesity: its decrease during and after total fasting. Acta Med. Hung. 43:55-58
37. Hanniman EA, Lambert G, McCarthy TC, Sinal CJ. 2005. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 46:2595-604
38. Hara E. 2015. Relationship between obesity, gut microbiome and hepatocellular carcinoma development. Dig. Dis. 33:346-50
39. Haselow K, Bode JG, Wammers M, Ehlting C, Keitel V, et al. 2013. Bile acids PKA-dependently induce a switch of the IL-10/IL-12 ratio and reduce proinflammatory capability of human macrophages. J. Leukoc. Biol. 94:1253-64
40. Haverkamp S. 2012. Glycine receptor diversity in the mammalian retina. In Webvision: The Organization of the Retina and Visual System, ed. H Kolb, E Fernandez, R Nelson. Salt Lake City, UT: Univ. Utah Health Sci. Cent.
41. Hofmann AF, Eckmann L. 2006. How bile acids confer gut mucosal protection against bacteria. PNAS 103:4333-34
42. Ichikawa R, Takayama T, Yoneno K, Kamada N, Kitazume MT, et al. 2012. Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway. Immunology 136:153-62
43. Imae M, Asano T, Murakami S. 2014. Potential role of taurine in the prevention of diabetes and metabolic syndrome. Amino Acids 46:81-88
44. Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, et al. 2006. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. PNAS 103:3920-25
45. Islam KB, Fukiya S, Hagio M, Fujii N, Ishizuka S, et al. 2011. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 141:1773-81
46. JacksonH, Solaymani-DodaranM, Card TR, Aithal GP, Logan R, West J. 2007. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology 46:1131-37
47. Jones BV, Begley M, Hill C, GahanCG, Marchesi JR. 2008. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. PNAS 105:13580-85
48. Jones ML, Tomaro-Duchesneau C, Martoni CJ, Prakash S. 2013. Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications. Expert Opin. Biol. Ther. 13:631-42
49. Joyce SA, GahanCG. 2014. The gut microbiota and themetabolic health of the host. Curr. Opin. Gastroenterol. 30:120-27
50. Joyce SA, MacSharry J, Casey PG, Kinsella M, Murphy EF, et al. 2014a. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. PNAS 111:7421-26
51. Joyce SA, Shanahan F, Hill C, Gahan CG. 2014b. Bacterial bile salt hydrolase in host metabolism: potential for influencing gastrointestinal microbe-host crosstalk. Gut Microbes 5:669-74
52. Kersten S. 2014. Integrated physiology and systems biology of PPAR. Mol. Metab. 3:354-71
53. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, et al. 2013. Intestinal microbiotametabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19:576-85
54. Kurz AK, Graf D, Schmitt M, Vom Dahl S, Haussinger D. 2001. Tauroursodesoxycholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats. Gastroenterology 121:407-19
55. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, et al. 2013. Richness of human gut microbiome correlates with metabolic markers. Nature 500:541-46
56. Li F, Jiang C, Krausz KW, Li Y, Albert I, et al. 2013. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat. Commun. 4:2384
57. Li T, Chiang JY. 2014. Bile acid signaling in metabolic disease and drug therapy. Pharmacol. Rev. 66:948-83
58. Lim SC, Han SI. 2015. Ursodeoxycholic acid effectively kills drug-resistant gastric cancer cells through induction of autophagic death. Oncol. Rep. 34:1261-68
59. Lin J. 2014. Antibiotic growth promoters enhance animal production by targeting intestinal bile salt hydrolase and its producers. Front. Microbiol. 5:33
60. Lin J, Negga R, Zeng X, Smith K. 2014. Effect of bile salt hydrolase inhibitors on a bile salt hydrolase from Lactobacillus acidophilus. Pathogens 3:947-56
61. Liou AP, Paziuk M, Luevano JM Jr, Machineni S, Turnbaugh PJ, Kaplan LM. 2013. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci. Transl. Med. 5:178ra41
62. Lorbek G, Lewinska M, Rozman D. 2012. Cytochrome P450s in the synthesis of cholesterol and bile acids- from mouse models to human diseases. FEBS J. 279:1516-33
63. Lund EG, Xie C, Kotti T, Turley SD, Dietschy JM, Russell DW. 2003. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J. Biol. Chem. 278:22980-88
64. Luo J, Ko B, Elliott M, Zhou M, Lindhout DA, et al. 2014. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci. Transl. Med. 6:247ra100
65. Ma K, Saha PK, Chan L, Moore DD. 2006. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Investig. 116:1102-9
66. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, et al. 1995. The nuclear receptor superfamily: the second decade. Cell 83:835-39
67. Mano N, Goto T, Uchida M, Nishimura K, Ando M, et al. 2004. Presence of protein-bound unconjugated bile acids in the cytoplasmic fraction of rat brain. J. Lipid Res. 45:295-300
68. Martoni CJ, Labbe A, Ganopolsky JG, Prakash S, Jones ML. 2015. Changes in bile acids, FGF-19 and sterol absorption in response to bile salt hydrolase active L. Reuteri NCIMB 30242. Gut Microbes 6:57-65
69. Mazuy C, Helleboid A, Staels B, Lefebvre P. 2015. Nuclear bile acid signaling through the farnesoid X receptor. Cell. Mol. Life Sci. 72:1631-50
70. Mencarelli A, Renga B, Distrutti E, Fiorucci S. 2009. Antiatherosclerotic effect of farnesoid X receptor. Am. J. Physiol. Heart Circ. Physiol. 296:H272-81
71. Mencarelli A, Renga B, Migliorati M, Cipriani S, Distrutti E, et al. 2009. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J. Immunol. 183:6657-66
72. Miras AD, le Roux CW. 2014. Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery? Int. J. Obes. 38:325-33
73. Miyata M, Takamatsu Y, Kuribayashi H, Yamazoe Y. 2009. Administration of ampicillin elevates hepatic primary bile acid synthesis through suppression of ileal fibroblast growth factor 15 expression. J. Pharmacol. Exp. Ther. 331:1079-85
74. MonteMJ, Marin JJ, Antelo A, Vazquez-Tato J. 2009. Bile acids: chemistry, physiology, and pathophysiology. World J. Gastroenterol. 15:804-16
75. Mroz MS, Keating N, Ward JB, Sarker R, Amu S, et al. 2014. Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo. Gut 63:808-17
76. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, et al. 2013. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145:574-82. E1
77. Murphy EF, Clarke SF, Marques TM, Hill C, Stanton C, et al. 2013. Antimicrobials: strategies for targeting obesity and metabolic health? Gut Microbes 4:48-53
78. Neff KJ, Chuah LL, Aasheim ET, Jackson S, Dubb SS, et al. 2014. Beyond weight loss: evaluating the multiple benefits of bariatric surgery after Roux-en-Y gastric bypass and adjustable gastric band. Obes. Surg. 24:684-91
79. Ogilvie LA, Jones BV. 2012. Dysbiosis modulates capacity for bile acid modification in the gut microbiomes of patients with inflammatory bowel disease: a mechanism and marker of disease? Gut 61:1642-43
80. Ohkohchi N, Andoh T, Izumi U, Igarashi Y, Ohi R. 1997. Disorder of bile acid metabolism in children with short bowel syndrome. J. Gastroenterol. 32:472-79
81. Oja SS, Saransaari P. 2007. Pharmacology of taurine. Proc. West Pharmacol. Soc. 50:8-15
82. Pereira-Fantini PM, Lapthorne S, Joyce SA, Dellios NL, Wilson G, et al. 2014. Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver disease. J. Hepatol. 61:1115-25
83. Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B. 2003. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol. Endocrinol. 17:259-72
84. Prawitt J, Abdelkarim M, Stroeve JH, Popescu I, DuezH, et al. 2011. FarnesoidXreceptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 60:1861-71
85. Prinz P, Hofmann T, Ahnis A, Elbelt U, Goebel-Stengel M, et al. 2015. Plasma bile acids show a positive correlation with body mass index and are negatively associated with cognitive restraint of eating in obese patients. Front. Neurosci. 9:199
86. Quinn M, McMillin M, Galindo C, Frampton G, Pae HY, DeMorrow S. 2014. Bile acids permeabilize the blood brain barrier after bile duct ligation in rats via Rac1-dependent mechanisms. Dig. Liver Dis. 46:527-34
87. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, et al. 2013. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341:1241214
88. Ridlon JM, Alves JM, Hylemon PB, Bajaj JS. 2013. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes 4:382-87
89. Ridlon JM, Hylemon PB. 2012. Identification and characterization of two bile acid coenzyme A transferases from Clostridium scindens, a bile acid 7-dehydroxylating intestinal bacterium. J. Lipid Res. 53:66-76
90. Ridlon JM, Kang DJ, Hylemon PB. 2006. Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47:241-59
91. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. 2014. Bile acids and the gut microbiome. Curr. Opin. Gastroenterol. 30:332-38
92. Ripps H, ShenW. 2012. Review: taurine: a "very essential" amino acid. Mol. Vis. 18:2673-86
93. Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A, et al. 2014. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509:183-88
94. Sayin SI, Wahlstrom A, Felin J, Jantti S, Marschall HU, et al. 2013. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17:225-35
95. Schaap FG, Trauner M, Jansen PL. 2014. Bile acid receptors as targets for drug development. Nat. Rev. Gastroenterol. Hepatol. 11:55-67
96. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, et al. 2012. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N. Engl. J. Med. 366:1567-76
97. Seedorf H, Griffin NW, Ridaura VK, Reyes A, Cheng J, et al. 2014. Bacteria from diverse habitats colonize and compete in the mouse gut. Cell 159:253-66
98. Seeley RJ, Chambers AP, Sandoval DA. 2015. The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes. Cell Metab. 21:369-78
99. Silva T, Teixeira J, Remiao F, Borges F. 2013. Alzheimer's disease, cholesterol, and statins: the junctions of important metabolic pathways. Angew. Chem. Int. Ed. Engl. 52:1110-21
100. Sjostrom L, Gummesson A, Sjostrom CD, Narbro K, Peltonen M, et al. 2009. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 10:653-62
101. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, et al. 2007. Effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med. 357:741-52
102. Sjostrom L, Peltonen M, Jacobson P, Sjostrom CD, Karason K, et al. 2012. Bariatric surgery and long-term cardiovascular events. JAMA 307:56-65
103. Smith K, Zeng X, Lin J. 2014. Discovery of bile salt hydrolase inhibitors using an efficient high-throughput screening system. PLOS ONE 9:e85344
104. Sorg JA, Sonenshein AL. 2008. Bile salts and glycine as cogerminants for Clostridium difficile spores. J. Bacteriol. 190:2505-12
105. Swann JR, Want EJ, Geier FM, Spagou K, Wilson ID, et al. 2011. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. PNAS 108(Suppl. 1):4523-30
106. Sweeney TE, Morton JM. 2014. Metabolic surgery: action via hormonal milieu changes, changes in bile acids or gut microbiota A summary of the literature. Best Pract. Res. Clin. Gastroenterol. 28:727-40
107. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, et al. 2013. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 368:1575-84
108. Thaiss CA, Zeevi D, Levy M, Zilberman-Schapira G, Suez J, et al. 2014. Transkingdom control ofmicrobiota diurnal oscillations promotes metabolic homeostasis. Cell 159:514-29
109. Uchida K, Nomura Y, KadowakiM, Takase H, Takano K, Takeuchi N. 1978. Age-related changes in cholesterol and bile acid metabolism in rats. J. Lipid Res. 19:544-52
110. Uranga RM, Keller JN. 2010. Diet and age interactions with regards to cholesterol regulation and brain pathogenesis. Curr. Gerontol. Geriatr. Res. 2010:219683
111. Vang S, Longley K, Steer CJ, Low WC. 2014. The unexpected uses of urso-and tauroursodeoxycholic acid in the treatment of non-liver diseases. Glob. Adv. Health Med. 3:58-69
112. Vaquero J, Monte MJ, Dominguez M, Muntane J, Marin JJ. 2013. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition. Biochem. Pharmacol. 86:926-39
113. Voigt RM, Forsyth CB, Green SJ, Mutlu E, Engen P, et al. 2014. Circadian disorganization alters intestinal microbiota. PLOS ONE 9:e97500
114. Vrieze A, Out C, Fuentes S, Jonker L, Reuling I, et al. 2014. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J. Hepatol. 60:824-31
115. Walters JR, Appleby RN. 2015. A variant of FGF19 for treatment of disorders of cholestasis and bile acid metabolism. Ann. Transl. Med. 3:S7
116. Walters JR, Johnston IM, Nolan JD, Vassie C, Pruzanski ME, Shapiro DA. 2015. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment. Pharmacol. Ther. 41:54-64
117. Walters JR, Tasleem AM, OmerOS, Brydon WG, Dew T, le Roux CW. 2009. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin. Gastroenterol. Hepatol. 7:1189-94
118. Wang Y, Karu K, Meljon A, Turton J, Yau JL, et al. 2014. 24S, 25-Epoxycholesterol in mouse and rat brain. Biochem. Biophys. Res. Commun. 449:229-34
119. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, et al. 2011. Gut florametabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472:57-63
120. Ward JB, Mroz MS, Keely SJ. 2013. The bile acid receptor, TGR5, regulates basal and cholinergic-induced secretory responses in rat colon. Neurogastroenterol. Motil. 25:708-11
121. Watanabe M, Horai Y, Houten SM, Morimoto K, Sugizaki T, et al. 2011. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J. Biol. Chem. 286:26913-20
122. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, et al. 2006. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439:484-89
123. Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ. 2009. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoeapredominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 30:707-17
124. Wewalka M, Patti M-E, Barbato C, Houten SM, Goldfine AB. 2014. Fasting serum taurine-conjugated bile acids are elevated in type 2 diabetes and do not change with intensification of insulin. J. Clin. Endocrinol. Metab. 99:1442-51
125. Wong BS, Camilleri M, Carlson P, McKinzie S, Busciglio I, et al. 2012. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin. Gastroenterol. Hepatol. 10:1009-15. E3
126. Xie G, Zhong W, Li H, Li Q, Qiu Y, et al. 2013. Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption. FASEB J. 27:3583-93
127. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, et al. 2013. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499:97-101
128. Zhang S, Wang J, Liu Q, Harnish DC. 2009. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 51:380-88
129. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, et al. 2006. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. PNAS 103:1006-11
130. Zhang Y, Wang X, Vales C, Lee FY, Lee H, et al. 2006. FXR deficiency causes reduced atherosclerosis in Ldlr/ mice. Arterioscler. Thromb. Vasc. Biol. 26:2316-21
131. Zheng ZH, Lv GP, Si SY, Dong YS, Zhao BH, et al. 2007. A cell-based high-throughput screening assay for Farnesoid X receptor agonists. Biomed. Environ. Sci. 20:465-69
132. Zhou H, Hylemon PB. 2014. Bile acids are nutrient signaling hormones. Steroids 86:62-68